Monday, October 25, 2010 8:15:53 AM
Oct 25, 2010: Avid Bioservices to Present at IBC's Preclinical Scale Bioprocessing Conference November 1-3, 2010
• Presenting Comparability of Single-Use Bioreactors for Antibody Production
http://www.marketwire.com/press-release/Avid-Bioservices-Present-IBCs-Preclinical-Scale-Bioprocessing-Conference-November-1-NASDAQ-PPHM-1340304.htm
TUSTIN, CA and BOSTON, MA--(Marketwire - October 25, 2010) - Avid Bioservices, Inc., a leading provider of integrated commercial and clinical manufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc., announced that company representatives will present at IBC's Preclinical Scale Bioprocessing Conference, Strategies to Improve the Speed, Quality and Cost of Early Bioprocess Development, on Monday, November 1, 2010 at 5:00pm EDT in Boston, MA. A pioneer in the early adoption of single-use bioreactors (S.U.B.), Avid will highlight data comparing its S.U.B. (Thermo Scientific HyClone S.U.B.) and its traditional stainless steel bioreactors at the company's cGMP manufacturing facility in Orange County, CA.
"As we help clients accelerate the drug development process and time to market, our early adoption of single-use bioreactors has been critical in achieving efficiencies and flexibility in antibody biomanufacturing," said Richard Richieri, senior director, client technical services, of Avid Bioservices. "The consistent data we have seen from using our traditional bioreactor and our S.U.B. allow us to offer flexible and scalable biomanufacturing services to our clients."
Avid's presentation is titled "Large Scale Cell Culture Production Using Single Use Technology, Comparison of the 1,000L S.U.B. vs. 1,000L Stainless Steel Bioreactor" and will take place in the Olympia room of the Hyatt Harborside Hotel at 5:00pm EDT on Monday, November 1, 2010.
ABOUT IBC'S EARLY DEVELOPMENT FORUMS
IBC's Preclinical Scale Bioprocessing Conference will take place November 1-3, 2010 at the Hyatt Harborside Hotel in Boston, MA. IBC's Early Development forums provide a venue for research, development and regulatory scientists to support early-stage process and analytical development. The 7th conference in this series, Preclinical Scale Bioprocessing seeks to provide strategies to navigate the critical early stage of bioprocess development to conserve resources, optimize product quality and support a successful IND filing. For additional information on this conference, please visit http://www.ibclifesciences.com/preclinical/overview.xml .
ABOUT THERMO SCIENTIFIC HYCLONE S.U.B.
The Thermo Scientific HyClone S.U.B. consists of a reusable stainless steel outer support container and S.U.B. BioProcess Container (BPC®) that integrates with existing bioreactor control systems, providing the advantages of single-use bioprocessing without having to install a complete new bioreactor system. The retrofit product replaces the stainless steel bioreactor vessel in existing bioreactor systems, making it a flexible, rapid and economic option to increase bioreactor capacity.
ABOUT AVID BIOSERVICES
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support manufacturing of cGMP commercial and clinical products. With over 10 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cell banking, stability testing, clinical and commercial product manufacturing and purification, bulk packaging, final product filling and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, analytical methods development and product characterization. For more information about Avid, please visit http://www.avidbio.com .
ABOUT PEREGRINE PHARMACEUTICALS
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing 3 separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com .
Contact: Amy Figueroa, Peregrine Pharmaceuticals, (800) 987-8256, info@peregrineinc.com
= = = = = = = = = =
Nov1-3 2010: “IBC Preclinical Scale Bioprocessing 2010”, Boston
“Strategies to Improve the Speed, Quality, and Cost of Early Bioprocess Development”
http://www.ibclifesciences.com/preclinical
2010 Exhibitor (per Avid website): Avid Bioservices
= = = = = = = = = = = = =
AVID BIOSERVICES, Inc. (Peregrine's Mfg. Subsidiary): http://www.avidbio.com
...Avid Total Services (CMO + Govt + PPHM) for 12mos. ended 4-30-10: $30mm (per C.Eso 7-14-10 CC)
9-9-10 PPHM's Revs & Burns By Qtr Table, updated thru FY'11/Q1 (q/e 7-31-10): http://tinyurl.com/2valhbz
11-1-10: VP R.Richieri presents Avid’s SUB’s at IBC BioProc. Conf. http://tinyurl.com/23yyegk
10-4-10: Avid Wins Bioproduction Contract From Affitech for R84: http://tinyurl.com/27nfs9t
6-15-10: VP R.Richieri presents Avid’s SUB’s at IBC’s ‘Single-Use’; panelist at ‘Vaccines-Prod’ http://tinyurl.com/26zrr22
6-14-10: Avid adds ‘Line #4 FILL-FINISH’ capability, CMOLocator.com http://tinyurl.com/3xgu3ox
5-3-10: PPHM leases addl. 11,000sq adjacent space (Avid exp?): http://tinyurl.com/327dk2j
4-5-10: Avid & Halozyme Expand Commercial Supply Relationship: http://tinyurl.com/yfdgsom
…”the companies extended their existing commercial supply agreement (CSA) for rHuPH20 and signed a new CSA for addl. partnered product candidates such as subcutaneous HERCEPTIN & GAMMAGARD with rHuPH20.”
Apr’10: Contract-Pharma article on SUB’s quotes 3 Avid execs, Yoshioka/Richieri/Eso: http://tinyurl.com/yk4zbkd
3-16-10: VP Rich Richieri presents Hyclone bioreactors data at Thermo Scientific Workshop http://tinyurl.com/yln93zx
4 articles in 2009 ref. Avid (Disposables, Biosimilars, Economy, Revs): http://tinyurl.com/yz9mcht
...12-14-09: ‘Avid’s Q2 Revs Rise 440%’, VP C.Eso comments (Outsourcing) http://tinyurl.com/3xgu3ox
9-21-09: Avid becomes sole U.S. W.Coast CMO in Boehringer Ingelheim's Global Prod. Alliance Network http://tinyurl.com/l9nf4n
8-28-09: Avid adds Truc Le as COO & Chris Eso as VP/Bus.Oper. http://tinyurl.com/m85erv
5-13-09: VP Rich Richieri presents Avid’s tech. at BIO-INTL'09 http://tinyurl.com/oe3lsm PDF: http://tinyurl.com/yk78fk5
11-10-08: Avid expands capacity by adding 100L & 1000L Hyclone bioreactors: http://tinyurl.com/69qgl5
10-27-08: Avid Becomes CMO for Catalyst Biosciences’ protease candidate CB813: http://tinyurl.com/5fg7zg
6-25-08: Avid Selected as 1st U.S. CMO for DSM/Crucell’s PER.C6 Cell Line: http://tinyurl.com/4geqxw
…9-30-08 Crucell gets $40mm NIAID/BARDA award for Ebola-Marburg Vaccine: http://tinyurl.com/4wc2of
8-6-10: Avid & Cook remain Halozyme's 2 CMO's: http://tinyurl.com/2a89bvj
7-14-08: Avid is CMO for Arius Research’s lead drug, “AR001 Targeting CD44”: http://tinyurl.com/6hrwrt
...7-23-08 Roche buys Arius for $190mm : http://tinyurl.com/5fg6jd
Recent CDMO News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:31:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:30:26 AM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • HLYK • Mar 19, 2024 8:00 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM